Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchivePavilion REIT Posts Q3 Revenue of 227.3 Million RGT

Live News EQUITY FLASH M impact Oct 22, 2026, 10:30 AM UTC

Pavilion REIT Posts Q3 Revenue of 227.3 Million RGT

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

PAVREIT

Related stories

HPCL Reports 9% Drop in Second-Quarter Profit on Higher Costs India's Hindustan Petroleum Corp said higher tax expenses and a sharp spike in crude prices squeezed fuel-retailing margins. M impact | EQUITY | Oct 22, 2026, 12:17 PM UTC Norfolk Southern Third-Quarter Railway Volume Rose 3% M impact | EQUITY | Oct 22, 2026, 12:15 PM UTC Sapphire Foods Q2 Loss Narrows to Rs 1.5 Crore as Revenue Jumps 20% Sapphire Foods reported a narrower consolidated net loss and 20% revenue growth in the September quarter. KFC revenue reached Rs 888 crore, up nearly 20% year on year. M impact | EQUITY | Oct 22, 2026, 12:15 PM UTC ACNB Reports Record Third-Quarter Net Income of $15.7 Million ACNB reported diluted earnings of $1.55 per share, versus $1.42 a year earlier. Net interest income rose to $34.8 million, while net interest margin held at 4.56% from the prior qu M impact | EQUITY | Oct 22, 2026, 12:13 PM UTC Atlas Energy Solutions Secures Up to $424 Million Bridge Loan Atlas Energy Solutions entered into a bridge loan agreement providing up to $424 million in term loans, with the option to request up to $286 million in additional commitments subj M impact | EQUITY | Oct 22, 2026, 12:13 PM UTC AstraZeneca Launches ZEGFROVY in the US for NSCLC AstraZeneca said ZEGFROVY is available in the US for adults with EGFR exon 20 insertion-mutated NSCLC after platinum chemotherapy. The FDA granted accelerated approval based on a 4 M impact | EQUITY | Oct 22, 2026, 12:11 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.